Pediatric Blood & Cancer 2014-05-01

Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab.

Sule Unal, Erdal Sag, Baris Kuskonmaz, Selman Kesici, Benan Bayrakci, Deniz C Ayvaz, Ilhan Tezcan, Dilek Yalnızoglu, Duygu Uckan

Index: Pediatr. Blood Cancer 61(5) , 928-30, (2014)

Full Text: HTML

Abstract

Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2-year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post-transplant +22nd month and required respiratory support with mechanical ventilation. She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance. She is currently asymptomatic on the 6th month of follow-up.© 2013 Wiley Periodicals, Inc.